quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:15:13·9d
SECFiling
LB Pharmaceuticals Inc logo

SEC Form EFFECT filed by LB Pharmaceuticals Inc

LBRX· LB Pharmaceuticals Inc
Health Care
Original source

Companies

  • LBRX
    LB Pharmaceuticals Inc
    Health Care

Recent analyst ratings

  • Apr 10UpdateCraig Hallum$36.00
  • Jan 9UpdateRoth Capital-
  • Oct 6UpdateStifel$27.00
  • Oct 6UpdatePiper Sandler$78.00
  • Oct 6UpdateLeerink Partners$34.00

Related

  • SEC15h
    SEC Form DEFA14A filed by LB Pharmaceuticals Inc
  • SEC15h
    SEC Form DEF 14A filed by LB Pharmaceuticals Inc
  • PR1d
    LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
  • SEC9d
    SEC Form 424B3 filed by LB Pharmaceuticals Inc
  • ANALYST13d
    Craig Hallum initiated coverage on LB Pharmaceuticals with a new price target
  • PR14d
    LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference
  • SEC17d
    SEC Form S-1 filed by LB Pharmaceuticals Inc
  • PR27d
    LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022